The B-cell depletion therapy (Rituximab) provides more benefit to MuSK-MG patients than AChR-MG patients (Evoli et al., 2008, 2018; Díaz-Manera et al., 2012; Evoli and Padura, 2013; Tandan et al., 2017; Morren and Li, 2018; Beecher et al., 2019; Di Stefano et al., 2020; Huda, 2020; Litchman et al., 2020). Here, MUSK is linked to myasthenia gravis.